Molecule Group's chief operating officer, Brendan O'Brien, has bought 41,500 shares on AIM in two tranches, on 8 and 12 October 2026. On our calculation, the purchases were worth about £88,346, and they take his holding to 591,500 shares, or 2.2% of the company.
What was announced
On 13 October 2026, Molecule Group (LSE:MOL) disclosed that Brendan O'Brien, its chief operating officer, had bought shares in the company. The dealing was disclosed in a notification of a transaction by a person discharging managerial responsibilities (PDMR), as required under the UK Market Abuse Regulation.
Mr O'Brien bought 18,300 shares at £2.14 each on 8 October 2026 and a further 23,200 shares at £2.12 each on 12 October 2026, a total of 41,500 shares. Both transactions were carried out on AIM. The transactions are described as purchases. They are not awards, the vesting of share-based incentives or sales to cover tax, so they represent shares acquired with his own funds rather than shares received as remuneration.
The numbers
On our calculation, the first tranche of 18,300 shares at £2.14 cost about £39,162 and the second tranche of 23,200 shares at £2.12 cost about £49,184. That gives a combined consideration of about £88,346, the figure behind the headline, and implies an average price of roughly £2.13 per share across the two purchases.
After the purchases, Mr O'Brien holds 591,500 shares, which the company puts at 2.2% of its issued share capital. On our calculation, he held 550,000 shares before these transactions, so the purchases increased his holding by about 7.5%. Also on our calculation, a holding of 591,500 shares at 2.2% implies roughly 27 million shares in issue. That figure is approximate, because the stated percentage is rounded.
Background and context
PDMR notifications are regulatory disclosures that record a transaction once it has taken place. Under the UK Market Abuse Regulation, directors and other senior managers must notify both the company and the Financial Conduct Authority of their dealings, and the company must then make the information public promptly. These notices exist to give the market transparency about trading by people with senior roles at a company.
The notification does not give the reasons for the purchases. It also includes no comment from the company on its trading, its outlook or any recent corporate events, so none is reported here. A dealing notice on its own does not indicate how the company is performing or how its shares might perform.
What to watch next
Any further PDMR notifications will show whether Mr O'Brien or other directors deal again in the shares. For information on Molecule Group's operating and financial performance, investors would need to look to its separate trading updates and results announcements, which fall outside the scope of this disclosure.






Please wait processing your request...